TY - JOUR
T1 - Bactericidal/permeability-increasing protein (BPI) and BPI homologs at mucosal sites
AU - Canny, Geraldine
AU - Levy, Ofer
N1 - Funding Information:
The authors acknowledge the contributions of Sean Colgan, Peter Elsbach and Jerrold Weiss for their mentorship. G.C. is funded by the Swiss National Science Foundation, Novartis Foundation and the Roche Research Foundation and O.L. is funded by NIH RO1 AI067353–01A1, a Dana Human Immunology Award and XOMA (US LLC). We thank Patrick Bibbins at Children’s Hospital Boston for graphic design of Figure 1 .
PY - 2008/11
Y1 - 2008/11
N2 - At mucosal surfaces, we must co-exist with a high density of diverse microorganisms; therefore, protection against these occurs on multiple levels. Leukocyte- and epithelial derived-antimicrobial peptides and proteins (AMPs) comprise an essential component of immune defense. These molecules possess antibacterial, antifungal and signalling properties and probably contribute to defence and maintenance of homeostasis between the host and commensal microorganisms. Among these AMPs is bactericidal/permeability-increasing protein (BPI), an antimicrobial protein with potent endotoxin-neutralising activity, and several homologs. This review explores the roles of BPI and and its homologs at the mucosal interface. Congeners of BPI are under biopharmaceutical development as novel anti-infective agents, highlighting the potential therapeutic relevance of this protein family.
AB - At mucosal surfaces, we must co-exist with a high density of diverse microorganisms; therefore, protection against these occurs on multiple levels. Leukocyte- and epithelial derived-antimicrobial peptides and proteins (AMPs) comprise an essential component of immune defense. These molecules possess antibacterial, antifungal and signalling properties and probably contribute to defence and maintenance of homeostasis between the host and commensal microorganisms. Among these AMPs is bactericidal/permeability-increasing protein (BPI), an antimicrobial protein with potent endotoxin-neutralising activity, and several homologs. This review explores the roles of BPI and and its homologs at the mucosal interface. Congeners of BPI are under biopharmaceutical development as novel anti-infective agents, highlighting the potential therapeutic relevance of this protein family.
UR - http://www.scopus.com/inward/record.url?scp=53849117421&partnerID=8YFLogxK
U2 - 10.1016/j.it.2008.07.012
DO - 10.1016/j.it.2008.07.012
M3 - Review article
C2 - 18838299
AN - SCOPUS:53849117421
VL - 29
SP - 541
EP - 547
JO - Trends in Immunology
JF - Trends in Immunology
SN - 1471-4906
IS - 11
ER -